- Home
- ASAN vs XENE Comparison
ASAN vs XENE Comparison
Compare ASAN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | XENE |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASAN | XENE |
|---|---|---|
| Price | $5.81 | $59.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $12.46 | ★ $67.17 |
| AVG Volume (30 Days) | ★ 6.4M | 977.9K |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $790,806,000.00 | $311,000.00 |
| Revenue This Year | $10.19 | N/A |
| Revenue Next Year | $7.91 | $2,436.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.25 | N/A |
| 52 Week Low | $5.38 | $28.19 |
| 52 Week High | $19.00 | $62.91 |
Technical Indicators
Market Signals| Indicator | ASAN | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 65.77 |
| Support Level | N/A | $39.93 |
| Resistance Level | $6.67 | $62.91 |
| Average True Range (ATR) | 0.42 | 1.81 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 34.50 | 92.31 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.